Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesColin F. Spraggs, Martine Piccart, Linda P. Briley et al.|The Pharmacogenomics Journal|2017Cited by 22